← Browse by Condition
Medical Condition

neoplasm metastasis

Total Trials
3
Recruiting Now
3
Trial Phases
Phase 2, Phase 3

ClinicalMetric tracks all active clinical trials for neoplasm metastasis sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — neoplasm metastasis Clinical Trials

How many clinical trials are currently recruiting for neoplasm metastasis?
ClinicalMetric currently tracks 3 actively recruiting clinical trials for neoplasm metastasis, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 3. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for neoplasm metastasis?
neoplasm metastasis research spans Phase 2 (1 trial), Phase 3 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a neoplasm metastasis clinical trial?
Eligibility criteria for neoplasm metastasis trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 2
1
Phase 3
1
Top Sponsors
Shandong Cancer Hospital and Institute 1 trial
Centre Hospitalier Universitaire de la Guadeloupe 1 trial
Eli Lilly and Company 1 trial

Recruiting Clinical Trials

NCT06532539 Phase 2
Recruiting
Cadonilimab With Chemoradiation for Recurrent and Oligometastatic Endometrial Carcinoma
Enrollment
30 pts
Location
China
Sponsor
Shandong Cancer Hospital and I...
View Trial →
NCT06046131
Recruiting
Clinical, Genetic and Environmental Determinants of Prostate Cancer Progression.
Enrollment
3,000 pts
Location
France, Guadeloupe
Sponsor
Centre Hospitalier Universitai...
View Trial →
NCT07213804 Phase 3
Recruiting
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
Enrollment
1,630 pts
Location
United States, Austr...
Sponsor
Eli Lilly and Company
View Trial →

Related Conditions

endometrial neoplasms (1) neoplasm recurrence local (1) prostatic neoplasm (1) adenocarcinoma (1) neoplasm recurrence (1) ovarian neoplasms (1) fallopian tube neoplasms (1) peritoneal neoplasms (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology